Magnesium is one of the few supplements with a real guideline endorsement for migraine prevention — the American Academy of Neurology and American Headache Society class it as "probably effective," their second-highest evidence tier.1 That's a genuinely different footing than most things marketed for migraine. But the guideline is decades old, the underlying trials are small, and the doses that produced results — generally 360–600mg of elemental magnesium a day — sit above what a single serving of most magnesium supplements provides, including ours. This article walks through what the trials actually found, what the dose gap means in practice, and why magnesium is an option to discuss with a doctor, not a stand-in for prescribed migraine treatment.
What the guideline actually says
In 2012, the Quality Standards Subcommittee of the American Academy of Neurology (AAN) and the American Headache Society (AHS) published an evidence-based guideline update on complementary treatments for episodic migraine prevention in adults.1 Magnesium was rated Level B — "probably effective," the second tier in a four-level system (A = established effective, B = probably effective, C = possibly effective, U = evidence inadequate/conflicting). That puts magnesium in the same evidence class as several non-prescription options clinicians already discuss with migraine patients, alongside riboflavin and feverfew.
Two things worth being direct about. First, "probably effective" is not "proven" — it's a real classification, not marketing shorthand, and it reflects a genuinely limited evidence base: a handful of small randomized trials, not a large modern trial program. Second, this guideline update is now over a decade old. A more recent narrative review (2025) reaffirmed that magnesium is generally recommended as a preventive option based on the accumulated trial evidence, while noting its main downside is dose-dependent gastrointestinal tolerability, not a safety signal beyond that.6 No major guideline has downgraded magnesium's classification since 2012, but the evidence base hasn't been meaningfully expanded either — a gap actual clinicians and researchers, not just marketing copy, have pointed out.5
The two trials behind the guideline
Peikert et al., 1996 (Cephalalgia). The most-cited trial: 81 adults with migraine were randomized to 600mg/day of magnesium (as trimagnesium dicitrate, roughly 24 mmol elemental magnesium) or placebo for 12 weeks, after a 4-week baseline period.2 In the final month of treatment, attack frequency dropped 41.6% in the magnesium group versus 15.8% with placebo (p<0.05), and migraine days and use of acute medication fell along with it. The main side effect was diarrhea and mild stomach upset, which is typical of magnesium at these doses and generally dose-dependent.
Facchinetti et al., 1991 (Headache). A smaller, earlier double-blind trial in 20 women with menstrual migraine tested 360mg/day of magnesium (as magnesium pyrrolidone carboxylic acid), taken from day 15 of the cycle through the onset of menstruation, across two treatment cycles.3 The magnesium group showed a lower pain total index and fewer days with headache than placebo — one of the earliest signals that magnesium might matter specifically around the hormonal drop that precedes a period, a pattern later work on menstrual migraine has continued to explore.
A 2018 systematic review examined the full body of magnesium-migraine trials together and found the evidence "suggestive but not conclusive" — real signal, run through a small number of heterogeneous, mostly small studies that haven't been replicated at scale.5 That's the honest state of the science: enough for a guideline body to call it probably effective, not enough to call it proven the way a prescription preventive is.
"Probably effective" is a real evidence classification — not proof, and not a reason to skip a doctor's diagnosis and prescribed care.
Who the trials suggest might benefit most
Across the trial evidence and the American Migraine Foundation's clinical summary, two subgroups come up repeatedly as the strongest candidates for a magnesium trial under a doctor's guidance: people with migraine with aura, and people with menstrual migraine tied to the drop in estrogen before a period.4 Intravenous magnesium sulfate — a different, clinician-administered intervention, not a supplement — has separately shown benefit for acute migraine with aura in emergency and clinic settings. That's a different use case from daily oral prevention and isn't what this article, or our product, addresses.
The dose gap: trials vs. a standard supplement serving
This is the part worth being upfront about. The trials behind the Level B rating used 360–600mg of elemental magnesium per day — meaningfully more than a single serving of most oral magnesium supplements, including ours.
None of this means the product "doesn't work" for migraine — it means the trial evidence and this specific product's labeled dose aren't the same thing, and we'd rather say that plainly than let the guideline's Level B rating imply more than the label actually delivers. If migraine prevention is the specific goal, that dose gap is exactly the kind of detail worth bringing to a doctor or headache specialist, who can weigh it against your health history, current medications, and the dose actually used in the trials.
Safety, interactions, and why this isn't a solo decision
Magnesium is generally well tolerated, and diarrhea is the most common side effect at higher doses — usually a sign to reduce the amount, not a safety emergency.26 But magnesium supplements can interact with certain antibiotics, some blood pressure and heart medications, and diuretics, and people with kidney disease need medical guidance before supplementing at all, since impaired kidneys can't clear excess magnesium normally.4 If you're currently on a prescribed migraine preventive (like a beta-blocker, anticonvulsant, or CGRP-targeted medication) or an acute treatment like a triptan, magnesium isn't something to add on your own to "stack" with what's prescribed — bring it up with the prescriber so they can check for interactions and decide whether it fits your treatment plan.
Bottom line
Magnesium has a real, guideline-recognized place in the migraine-prevention conversation — Level B, "probably effective," based on a small set of placebo-controlled trials showing meaningful reductions in attack frequency at doses of 360–600mg elemental magnesium daily. That's a legitimate, evidence-backed option some clinicians consider, not a cure and not proof it will work for any individual. Our Magnesium Glycinate delivers a fully disclosed 275mg elemental-magnesium serving — useful information for sleep and nervous-system support in its own right, but below the doses actually studied for migraine prevention. If migraine is what you're trying to address, the right first step is a conversation with a doctor or headache specialist about whether magnesium fits your situation, at what dose, and alongside what else.
This article is for informational purposes only and has not been evaluated by the FDA. It is not intended to diagnose, treat, cure, or prevent any disease. Speak with a healthcare provider before starting any new supplement, especially if you take medication or have an existing health condition.
References
- Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78(17):1346–1353. pubmed.ncbi.nlm.nih.gov/22529203
- Peikert A, Wilimzig C, Köhne-Völland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia. 1996;16(4):257–263. journals.sagepub.com/doi/10.1046/j.1468-2982.1996.1604257.x
- Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31(5):298–301. pubmed.ncbi.nlm.nih.gov/1860787
- American Migraine Foundation. Magnesium for Migraine. americanmigrainefoundation.org/resource-library/magnesium-migraine
- von Luckner A, Riederer F. Magnesium in Migraine Prophylaxis—Is There an Evidence-Based Rationale? A Systematic Review. Headache. 2018;58(2). doi:10.1111/head.13217. pubmed.ncbi.nlm.nih.gov/29131326
- Tepper SJ, Tepper K. Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur. Current Pain and Headache Reports. 2025;29(1):33. doi:10.1007/s11916-025-01358-3. link.springer.com/article/10.1007/s11916-025-01358-3
Related reading: Magnesium: The Complete Evidence-Based Guide, Does Magnesium Interact With Any Medications?, PMS, PMDD and Magnesium: What the Research Actually Shows, and our Magnesium Glycinate product page
Want to know what's actually in what you take? Join the list — no spam, just it straight.